Era of direct acting antivirals in chronic hepatitis C: Who will benefit?

doi:10.4254/wjh.v7.i24.2543

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 24

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7142)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series.

Item

Count

PDF

362

WORD

270

HTML

3161

Figures (1-1)

245

Sum=4038

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1476

Download

1628

Sum=3104

Oct 28, 2015 (publication date) through Dec 27, 2024

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Oct 28, 2015; 7(24): 2543-2550
Published online Oct 28, 2015. doi: 10.4254/wjh.v7.i24.2543

Open in New Tab Full Size Figure Download Figure

Figure 1 Current treatment model in the era of direct acting antivirals for chronic hepatitis C with respect to the patients who will benefit.

Citation: Fung J. Era of direct acting antivirals in chronic hepatitis C: Who will benefit? World J Hepatol 2015; 7(24): 2543-2550
URL: https://www.wjgnet.com/1948-5182/full/v7/i24/2543.htm
DOI: https://dx.doi.org/10.4254/wjh.v7.i24.2543